The Effect of Febuxostat on Kidney Outcomes in Patients with Chronic Kidney Disease and Asymptomatic Hyperuricemia: A Target Trial Emulation
In patients with stage 3-4 CKD and asymptomatic hyperuricemia, initiation of febuxostat was not associated with kidney outcomes, all-cause mortality, or MACE. Further studies are warranted to validate these findings.
Authors
- Zihan Fang (ORCID: https://orcid.org/0009-0000-6372-9876)
- Danna Zheng (ORCID: https://orcid.org/0000-0001-6415-8585)
- Ran He
- Bo Lin (ORCID: https://orcid.org/0000-0002-8153-0972)
- Tao Liu (ORCID: https://orcid.org/0000-0002-3648-5199)
- Qi Liu (ORCID: https://orcid.org/0009-0002-0475-3424)
Institutions
- Zhejiang Chinese Medical University (CN)
- Zhejiang Provincial People's Hospital (CN)
- Hangzhou Medical College (CN)
- Hangzhou City University
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1159/000550047
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00